ArticleMolecular cancer therapeutics2025

Preclinical Characterization of XB010: A Novel Antibody-Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4.

Brian A Mendelsohn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.